Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

ect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

Helle Husted, Sr. Director,

Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com.


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the 1600’s ... known as “The Doctor’s Plague.” In this time period, doctors ... This led, at times, to the death of vulnerable patients. ... don’t know that they may be unwittingly transmitting herpes viruses ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... with left main coronary disease who were treated ... SYNTAX-LE MANS is a substudy of the landmark ...
... ( http://www.gene2drug.com ) -- the ... science industry -- announces the publication of its latest ... for Commercial Suppliers, Vol. III." Given the highly ... report is designed to create opportunities for differentiation by ...
... Cholesterol Test for determining heart disease riskBIRMINGHAM, Ala., May ... developer of the VAP Cholesterol Test, has announced it ... and report apolipoprotein B100 (apoB) using the Vertical Auto ... of the VAP Cholesterol Test to accurately report apoB, ...
Cached Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III 2Atherotech Receives Patent for ApoB Measurement 2Atherotech Receives Patent for ApoB Measurement 3
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
(Date:7/9/2014)... The Cancer Genome Atlas (TCGA) Research Network have ... in lung adenocarcinoma, the most common subtype of ... expand the number of possible therapeutic targets for ... of patients with treatable mutations because many potent ... , TCGA is jointly funded and managed by ...
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... malaria vaccine development, scientists have used genomics,proteomics and ... on a molecular level as they move between ... complex life cycle is helping researchers,understand when different ... through seven different life stages. In turn, that,molecular-level ...
... seabirds accustomed to nesting on islands free of predators ... islands in the Aleutian archipelago in the 18th century. ... A study published this week in the journal Science ... rippled through entire island ecosystems, transforming the vegetation from ...
... innovation involving the sharing of genes between two ... between them for the,survival of both species populations.,The ... two species can give rise to a system ... - in this case, the production of,worker ants ...
Cached Biology News:Scientists reveal molecular secrets of the malaria parasite 2Scientists reveal molecular secrets of the malaria parasite 3Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 2Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 3Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 4Ants Genetic Engineering Leads To Species Interdependency 2
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: